Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (10067)	5/18/1999 9:14:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Bluegreen, the bugs could be hidden anywhere but if one does not find it, How do you know they are there? or even somewhere?. Even after many septic patients are dead, and many pieces are taken for bacterial and viral culture and PCR studies done from everywhere in the body an offending agent is not found. There are accepted clinical definitions of septic shock, and this patients could or could not be included in a trial. In Xoma's trial the clinical picture is the main entrance to the protocol, not the blood culture, not the cerebrospinal fluid culture. And even after conclusion they will most probably have to keep those patients in the analysis. Of course breakdown analysis by subgroups are acceptable, better if it was planned ahead, instead of post hoc. Bluegreen, you are entitled to a break. Each Xoma shareholders need one (I am assuming you are one). ncbi.nlm.nih.gov